Aditya Khosla Joins Iterative Scopes as Chief Technology Officer

Iterative Scopes has welcomed Aditya Khosla, Ph.D., to its executive ranks as chief technology officer (CTO), and member of the board of directors.
 
“We are thrilled to welcome Dr. Khosla to the Iterative Scopes team,” said Jonathan Ng, founder and CEO of Iterative Scopes. “Aditya brings a dedicated expertise in machine learning and improving patient outcomes with AI-powered healthcare technologies.”
 
In his role as CTO, Dr. Khosla will lead Iterative Scopes’ machine learning, product management, and software engineering teams.
 
Prior to joining Iterative Scopes, Khosla co-founded and was CTO of PathAI, leading the engineering and IT, machine learning, product, and recruiting teams. Co-founded in 2016, PathAI provides AI-powered research tools and services for pathology. During his tenure as CTO and co-founder, PathAI raised more than $250 million from investors, and now employs over 700 people.
 
“I’m excited to join Iterative Scopes as it makes significant inroads toward eliminating the disparities in care for the treatment of GI diseases,” said Khosla. “Its application of real-time, computer-vision-based technologies for precision medicine has the potential to benefit millions of patients at their point of care. I’m looking forward to applying my background and skills to drive discovery and predictive diagnostics that support the Iterative Scopes mission.”
 
Khosla completed his PhD in machine learning and computer vision at MIT. He has published more than 60 papers and patents in the fields of deep learning, computer vision, and computational pathology. According to Google Scholar, he is one of the top 100 most cited researchers in computer vision, with his work receiving over 55,000 citations.
 
“I’ve gotten to know Aditya over the past four years at MIT where I had the privilege of attending his lectures, as an advisor to the company and mentor to myself, and now coming full circle as a teammate at Iterative Scopes,” said Ng. “I am incredibly excited for Aditya to bring his scientific leadership and operational expertise to Iterative Scopes to unlock a new generation of AI tools in gastroenterology.”
 
Iterative Scopes applies artificial intelligence-based precision medicine for gastroenterology to help optimize clinical trials focused on inflammatory bowel disease treatment. The technology is also designed to potentially enhance colorectal cancer screenings. Its proprietary artificial intelligence and computer vision technologies could  potentially improve the accuracy and consistency of endoscopy readings. Iterative Scopes is initially applying these advances to impact polyp detection for colorectal cancer screenings and working to standardize disease severity characterization for inflammatory bowel disease. Longer term, the company plans to establish more meaningful endpoints for GI diseases, which may be better predictors of therapeutic response and disease outcomes. Spun out of MIT in 2017, the company is based in Cambridge, Mass.